Drug Profile
SCH 900117
Alternative Names: SCH900117Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action IL17A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Australia (SC, Injection)